Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp

Northern Trust Corp reduced its holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) by 8.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,211 shares of the company’s stock after selling 4,220 shares during the quarter. Northern Trust Corp owned about 0.16% of Vistagen Therapeutics worth $133,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of VTGN. R Squared Ltd acquired a new stake in shares of Vistagen Therapeutics in the 4th quarter valued at approximately $25,000. Boothbay Fund Management LLC acquired a new stake in shares of Vistagen Therapeutics in the 4th quarter valued at approximately $66,000. Prosperity Wealth Management Inc. acquired a new stake in shares of Vistagen Therapeutics in the 4th quarter valued at approximately $86,000. Landscape Capital Management L.L.C. acquired a new stake in shares of Vistagen Therapeutics in the 4th quarter valued at approximately $123,000. Finally, Blair William & Co. IL lifted its holdings in shares of Vistagen Therapeutics by 11.3% in the 4th quarter. Blair William & Co. IL now owns 98,466 shares of the company’s stock valued at $290,000 after buying an additional 10,000 shares during the period. 78.39% of the stock is owned by institutional investors and hedge funds.

Vistagen Therapeutics Price Performance

VTGN opened at $2.39 on Wednesday. The business has a 50 day simple moving average of $2.30 and a 200-day simple moving average of $2.60. The stock has a market capitalization of $68.98 million, a P/E ratio of -1.61 and a beta of 0.67. Vistagen Therapeutics, Inc. has a 12 month low of $1.90 and a 12 month high of $4.21.

Vistagen Therapeutics Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.